Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Moleculin Biotech, Inc. MBRX

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-33.6M
$-22.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -33.6
-15M-30M
2016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -256.0%
-100%-200%
201620202025
Three returns, three denominators.

Each USD of equity lost 256 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -22.7
-10M-20M
201620202025

Total assetsUSD 22.1M
EquityUSD 15.0M
CashUSD 8.9M
Current ratio1.41×

Equity funds 68% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
MBRX, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0−0.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌◌◌−0.59−1.76−1.95−0.46−0.53−0.40
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−256.0−123.6−71.6−44.3−32.9−104.1−88.5−75.7−61.1—
Shares out B0.000.000.000.000.030.010.050.030.020.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 43 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image